Log in to search using one of your social media accounts:

This page shows you the latest news items in this category. This is page number 9.

Study: Smoking Hikes Chances of Early Death for Rheumatoid Arthritis Patients
But risk declines after quitting, researchers find Source: HealthDay Related MedlinePlus Pages: Rheumatoid Arthritis, Smoking (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - April 4, 2016 Category: Consumer Health News Source Type: news

Study: Smoking Hikes Chances of Early Death for Rheumatoid Arthritis Patients
MONDAY, April 4, 2016 -- Smoking increases the chances of early death in people with rheumatoid arthritis, but quitting smoking significantly reduces that risk, a new study suggests. "This research provides important evidence that the risk of early... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 4, 2016 Category: Journals (General) Source Type: news

Suicide: Unseen Public Health Crisis
Longtime political consultant Ron Oliver divides his life into before Aug. 31, 2013, and after. That’s the morning he discovered that his wife of 31 years, Floy, had hanged herself in the garage of their North Little Rock home. “Since this happened to me, I wonder now when I read obituaries how many of them might have been suicides,” Oliver said last week. “Before, I never thought about it.” Some of them undoubtedly are. Suicide is the 10th most common cause of death in the United States, and Arkansas’ rate of suicide, 17.4 per 100,000 residents in 2014, is 30 percent higher than the nat...
Source: Arkansas Business - Health Care - April 4, 2016 Category: American Health Source Type: news

New study highlights long-term tolerability of anti-TNF therapies
This study provides reassuring evidence that anti-TNF therapies are effective in some patients over long periods of time; however, it also highlights the importance of selecting the right drug for each patient, as a large number of people with arthritis have to switch between therapies during a course of treatment."We are funding research which aims to help doctors predict which patients will respond best to which therapies, helping to speed up the time it takes to get the right treatment to the right patient." (Source: Arthritis Research UK)
Source: Arthritis Research UK - April 3, 2016 Category: Rheumatology Source Type: news

Samsung Nears European Approval for Near-Replica Version of Arthritis Drug
Samsung Group’s drug-development arm said it is on track to win European regulatory approval for a near-replica version of Johnson & Johnson’s blockbuster rheumatoid arthritis drug Remicade. (Source: WSJ.com: Health)
Source: WSJ.com: Health - April 1, 2016 Category: Pharmaceuticals Tags: PAID Source Type: news

Experimental Drug for Rheumatoid Arthritis Shows Promise
Title: Experimental Drug for Rheumatoid Arthritis Shows PromiseCategory: Health NewsCreated: 3/31/2016 12:00:00 AMLast Editorial Review: 4/1/2016 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - April 1, 2016 Category: Rheumatology Source Type: news

Baricitinib Offers Promise of Remission in Refractory RA Baricitinib Offers Promise of Remission in Refractory RA
The oral Janus kinase 1 and 2 inhibitor baricitinib significantly increased ACR20 response rates and improved physical function in patients with rheumatoid arthritis for whom other therapies had failed. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 1, 2016 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Experimental Drug for Rheumatoid Arthritis Shows Promise
Baricitinib helped patients who failed other treatments, researchers find (Source: U.S. News - Health)
Source: U.S. News - Health - March 31, 2016 Category: Consumer Health News Source Type: news

Experimental Drug for Rheumatoid Arthritis Shows Promise
Baricitinib helped patients who failed other treatments, researchers find Source: HealthDay Related MedlinePlus Page: Rheumatoid Arthritis (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - March 31, 2016 Category: Consumer Health News Source Type: news

New drug effective for refractory rheumatoid arthritis
Stephen FellerSTANFORD, Calif., March 31 (UPI) -- In a clinical trial, the drug baricitinib was shown to be effective in rheumatoid arthritis patients with lessening or no response to other treatments. (Source: Health News - UPI.com)
Source: Health News - UPI.com - March 31, 2016 Category: Consumer Health News Source Type: news

New drug for the treatment of rheumatoid arthritis shows promising success
In a clinical phase-3-study, an international research cooperation has achieved significant success with the drug Baricitinib for the treatment of rheumatoid arthritis. The test persons exhibited significantly less symptoms of the disorder. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 31, 2016 Category: Science Source Type: news

Experimental Drug for Rheumatoid Arthritis Shows Promise
THURSDAY, March 31, 2016 -- An experimental drug to treat rheumatoid arthritis showed promise in a new six-month trial. Baricitinib substantially reduced symptoms and improved daily physical functioning among people who failed other treatments for... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 31, 2016 Category: Journals (General) Source Type: news

Arthritis Research UK Fellow wins prestigious Garrod prize
Congratulations to Dr Helen McGettrick, a career development fellowship holder from the University of Birmingham, who has been awarded the prestigious Garrod prize. Awarded annually by the British Society of Rheumatology, this prize is open to scientists with a non-clinical background who are working in rheumatology or a related discipline. The award is named after Sir Alfred Baring Garrod, who was responsible for recognising the difference between osteoarthritis and rheumatoid arthritis and for initiating the thread test for uric acid in the blood. Helen’s research focuses on exploring the role played by synovial f...
Source: Arthritis Research UK - March 30, 2016 Category: Rheumatology Source Type: news

New Imaging Modality to Detect Inflammation in RA and OANew Imaging Modality to Detect Inflammation in RA and OA
Do we need new imaging modalities for the assessment of inflammation in rheumatoid arthritis and osteoarthritis? Annals of the Rheumatic Diseases (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - March 30, 2016 Category: Radiology Tags: Rheumatology Journal Article Source Type: news

We should be ashamed if we don’t pass Tobacco 21 laws
Follow me at @drClaire In the United States, the national drinking age is 21. States can make it younger, but if they do they lose federal highway funding. The idea is that youth less than 21 are more likely to run into trouble if they drink, and that having them wait until they are older is better. You can argue about whether this actually works, but the idea is a good one. And yet when it comes to tobacco, as far as the federal government is concerned, you just have to be 18. Which, for anyone who knows anything about what happens when youth smoke, makes no sense at all. It was really Mothers Against Drunk Driving (MADD)...
Source: New Harvard Health Information - March 29, 2016 Category: Consumer Health News Authors: Claire McCarthy, MD Tags: Addiction Behavioral Health Children's Health Parenting Prevention Smoking cessation tobacco 21 laws Source Type: news

RasGRP1 and RasGRP3 in Rheumatoid ArthritisRasGRP1 and RasGRP3 in Rheumatoid Arthritis
What roles do RasGRP1 and RasGRP3 play in rheumatoid arthritis pathophysiology? Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 29, 2016 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Benefits of anti-TNF treatment for psoriatic arthritis highlighted by study
This study was significant as it utilised data from patients in a real-world setting, rather than controlled test conditions. This provides doctors with a clearer view of how drugs work in routine clinical practice.A total of 420 biologic-naive patients with psoriatic arthritis, who were beginning treatment with the anti-TNF therapies adalimumab, etanercept or infliximab, were enrolled in the trial, with their progress followed over four years.Attention was paid to drug survival rates - the number of people remaining on treatment after a given period - as well as how many of the patients continued to rely on glucocorticoid...
Source: Arthritis Research UK - March 28, 2016 Category: Rheumatology Source Type: news

An Open Letter to the Boston Globe About Lyme Disease
Today, the Boston Globe editorial board spoke out against a bill "that would require insurers in Massachusetts to cover Lyme disease treatments for as long as a doctor says they're needed." The Globe writes: Lawmakers may have good intentions, but they don't possess the expertise to decide whether it's beneficial, cost-efficient, or safe, to keep using strong medicines to treat a condition the medical establishment doubts is real. Such questions should be resolved by a consensus of doctors and researchers -- and buttressed by convincing clinical date [sic] -- not determined by legislative mandate. Who among the Boston Glob...
Source: Healthy Living - The Huffington Post - March 28, 2016 Category: Consumer Health News Source Type: news

Smoking and RA: A Deadly Combination (CME/CE)
(MedPage Today) -- Medium-term mortality doubled in smokers with rheumatoid arthritis (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - March 27, 2016 Category: Geriatrics Source Type: news

Antibiotics Side Effects on the Mitochondria
Science is just beginning to understand how important your mitochondria are to warding off the diseases of aging. And, as usual, mainstream medicine is lagging way behind. Along with your telomeres, the cellular time keepers at the ends of your chromosomes, your mitochondria are another key component of the anti-aging equation. You see, these tiny organelles in your cells are the power plants that turn fuel into energy for your body. Healthy mitochondria keep you young and energetic.  Research shows that damaged mitochondria can lead to: Schizophrenia and bipolar disorder; Alzheimer’s and Parkinson’s disease; ...
Source: Al Sears, MD Natural Remedies - March 25, 2016 Category: Complementary Medicine Authors: Al Sears Tags: Natural Cures Source Type: news

Prooxidants may fix metabolic defect in arthritis-driving T cells
Researchers have uncovered a metabolic defect that spurs T cells to go rogue in rheumatoid arthritis patients. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 23, 2016 Category: Science Source Type: news

Claims that man flu 'really exists' are unsupported
Conclusion This small laboratory study points to specific biological mechanisms that might explain why women are more likely to suffer autoimmune disorders, such as SLE, than men. It found the second silenced copy of the X chromosome in women can be partially reactivated and express immune-related genes, instead of staying completely silent. Though this is a plausible reason for the overactive immune system found in SLE, it does not explain why men can also have the condition. Also, only SLE was investigated in this study and with blood samples from just five children with the condition. It is not clear at this stage how...
Source: NHS News Feed - March 23, 2016 Category: Consumer Health News Tags: Lifestyle/exercise Medical practice Source Type: news

Rheumatoid Arthritis Progression Rate Has Halved Since 1990 Rheumatoid Arthritis Progression Rate Has Halved Since 1990
The rate of radiographic progression in RA has decreased during the last 20 years, in tandem with changes in RA treatment practices. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 22, 2016 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Antisclerostin osteoporosis drugs might worsen or unmask rheumatoid arthritis
Antisclerostin monoclonal antibodies have shown their ability to increase bone density in phase II and III trials of men and women with osteoporosis but could potentially have the opposite effect in... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - March 21, 2016 Category: Endocrinology Source Type: news

Pfizer's Xeljanz meets goals in ulcerative colitis trials
(Reuters) - Pfizer Inc said on Friday its Xeljanz rheumatoid arthritis drug succeeded in meeting primary and secondary goals of a pair of late stage clinical trials in ulcerative colitis, results that could help pave the way for an additional approval for the oral medicine. (Source: Reuters: Health)
Source: Reuters: Health - March 18, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Mucosal Immune Tolerance in Rheumatoid ArthritisMucosal Immune Tolerance in Rheumatoid Arthritis
Does rheumatoid arthritis originate as mucosal inflammation in an extra-articular location? Read why many believe this is the case. Rheumatology (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - March 16, 2016 Category: Orthopaedics Tags: Rheumatology Journal Article Source Type: news

The Healing Power Of Poop May Surprise You
SAN DIEGO -- Last week at the inaugural Near Future Summit, a leadership conference of forward-thinking professionals, tech entrepreneur Peter Diamandis asked members of the audience to raise their hands if they'd been born vaginally. He then asked them to keep their hands raised if they had also been breastfed and if, in more recent years, they'd avoided antibiotics, Z-Paks and major surgery. In the end, just a few dozen people in the audience of 250 or so still had their hands up.  This wasn't just an exercise in TMI: Diamandis was hoping to assess the microbiome status of his listeners. All of the aforeme...
Source: Science - The Huffington Post - March 15, 2016 Category: Science Source Type: news

Conversations That Cut the Medical Bill (Jim Karrh On Marketing)
Considering all of the technical advances and new complexities in marketing today (such as social, digital and automation), I see the major opportunity for most organizations to be a decidedly analog one. Customer conversations — those interactions in real time, generally face to face — are ripe for improving engagement, service levels, loyalty and growth. A remarkable new study of the conversations between doctors and patients also shows that more proactive face-to-face interactions can even lower costs. The study comes from Duke University’s Fuqua School of Business, the Duke University School of Medici...
Source: Arkansas Business - Health Care - March 14, 2016 Category: American Health Source Type: news

Drug Combo Shuts Down Stem Cells, Tumor Growth in Lung Cancer
JACKSONVILLE, Fla. — Researchers on Mayo Clinic’s Florida campus have shut down one of the most common and lethal forms of lung cancer by combining the rheumatoid arthritis drug auranofin with an experimental targeted agent. The combination therapy worked in a laboratory study to stop lung adenocarcinoma associated with mutation of the KRAS gene. The [...] (Source: Mayo Clinic Florida News)
Source: Mayo Clinic Florida News - March 14, 2016 Category: Hospital Management Source Type: news

Regeneron and Sanofi Announce Topline Results of Phase 3 Monotherapy Study Demonstrating Superiority of Sarilumab vs. Adalimumab in Patients with Active Rheumatoid Arthritis
TARRYTOWN, N.Y. and PARIS, March 11, 2016 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a Phase 3 monotherapy study met its primary endpoint demonstrating that sarilumab was sup... BiopharmaceuticalsRegeneron Pharmaceuticals, Sanofi, sarilumab, rheumatoid arthritis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 11, 2016 Category: Pharmaceuticals Source Type: news

Xeljanz XR (tofacitinib citrate) Modified Release Tablets For the Treatment of Rheumatoid Arthritis
Xeljanz XR (tofacitinib citrate) is an 11mg once-daily oral JAK inhibitor developed by Pfizer for the treatment of moderate to severe Rheumatoid Arthritis (RA). (Source: Drug Development Technology)
Source: Drug Development Technology - March 11, 2016 Category: Pharmaceuticals Source Type: news

People with arthritis given equal say in research funding decisions
A pioneering pilot approach to patient involvement means Arthritis Research UK is blazing a trail among UK medical research charities to make sure people with arthritis are at the very heart of decision-making on research funding. Chris Macdonald, our research involvement manager, explains: "Each year we fund around £25m worth of research into the cause, treatment and cure of arthritis so people can live pain-free lives. What better way to make sure this research is of high quality and relevant to the lives of people with arthritis than to make sure their voice is heard loud and clear when we make funding decisions?...
Source: Arthritis Research UK - March 10, 2016 Category: Rheumatology Source Type: news

Research makes advances to treat osteoarthritis pain
For the 8.8 million people in the UK with osteoarthritis, research into new treatments to tackle osteoarthritis pain has the potential to dramatically improve quality of life. That’s why supporting innovative research in this area is one of our priorities, accounting for 25% of our research funding. We asked Dr Fiona Watt, consultant rheumatologist and senior clinical research fellow at our Centre for Osteoarthritis Pathogenesis at the Kennedy Institute of Rheumatology in Oxford, to share some of the latest developments: “Most of the patients who walk through the door to my clinic want to know how I can help t...
Source: Arthritis Research UK - March 10, 2016 Category: Rheumatology Source Type: news

Understanding pain – what it is and why we feel it
This issue we're looking at pain. Why? Because more than 1 in 6 people struggle with the pain of arthritis every day. Pain may be a common symptom experienced by millions, but it's a deeply complex issue.  Why do we feel pain? What is it about arthritis that causes pain? Why can two people have the same amount of deterioration in the joint but feel completely different levels of pain? These are just some of the questions you’ve asked about pain which our experts have helped us to answer. What is pain? Put simply, pain is a protective mechanism that alerts your brain when damage has occurred. It’s not jus...
Source: Arthritis Research UK - March 10, 2016 Category: Rheumatology Source Type: news

Serotonin deficiency implicated in rheumatoid arthritis
For the first time, serotonin (5-hydroxytryptamine, 5-HT) has been directly implicated in the pathophysiology of rheumatoid arthritis (RA). A new report shows that experimentally-induced RA in serotonin-deficient mice is worse than disease reported in controls and that some effects of RA can be reduced by serotonin or its agonists (compounds that activate serotonin receptors). (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 9, 2016 Category: Science Source Type: news

Serotonin deficiency implicated in rheumatoid arthritis
(Elsevier Health Sciences) For the first time, serotonin (5-hydroxytryptamine, 5-HT) has been directly implicated in the pathophysiology of rheumatoid arthritis (RA). A report in The American Journal of Pathology shows that experimentally-induced RA in serotonin-deficient mice is worse than disease reported in controls and that some effects of RA can be reduced by serotonin or its agonists (compounds that activate serotonin receptors). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 9, 2016 Category: Global & Universal Source Type: news

Rheumatoid Arthritis and Kidney Disease: Mayo Clinic Radio Health Minute
Rheumatoid arthritis is known for it's affects on the joints, but as we learn in this Mayo Clinic Radio Health Minute, the kidney can also be at risk. To listen, click the link below. Rheumatoid Arthritis and Kidney Disease (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 3, 2016 Category: Databases & Libraries Source Type: news

Taking vitamin D supplements may help winter-born babies
Taking vitamin D supplements during pregnancy may lead to stronger bones in babies born during the winter months, a new study published in The Lancet has shown. The research, which was part-funded by Arthritis Research UK, recruited more than 1,000 pregnant women to take part in a randomised, double-blind, placebo-controlled trial of vitamin D supplements in pregnancy. Increasing vitamin D in mothers Women were randomised to take either 1,000 units (25 microgrammes) of vitamin D every day or a matched placebo capsule from 14 week’s gestation until delivery of the baby. Results showed this dose of vitamin D was high...
Source: Arthritis Research UK - March 1, 2016 Category: Rheumatology Source Type: news

Rituximab Done: What's Next in Rheumatoid Arthritis?Rituximab Done: What's Next in Rheumatoid Arthritis?
Which biologic therapy is most effective after rituximab in rheumatoid arthritis patients? Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 29, 2016 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Autoimmune diseases gonna be defeated
(Lomonosov Moscow State University) An international team of scientists led by the Lomonosov Moscow State University group made a significant step in creating a new type of drug for treatment of autoimmune diseases, such as rheumatoid arthritis and Crohn's diseaase. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 29, 2016 Category: Infectious Diseases Source Type: news

Africa: Why Poor Rheumatoid Arthritis Sufferers in South Africa Have It Worse
[The Conversation Africa] In South Africa, studies show that patients suffering from rheumatoid arthritis can wait up to a year to be diagnosed and referred for therapy. In this time, their condition degenerates. Inflammation in their joints makes them painful, stiff and swollen. This leads to joint destruction and eventually disability before they have even been treated. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - February 26, 2016 Category: African Health Source Type: news

New report celebrates a decade of progress in chronic diseases
In the last 10 years, incredible progress has been made by the biopharmaceutical industry in the treatment of chronic diseases. With about half of all Americans, or 117 million people, living with one or more chronic health conditions, this innovation is more critical than ever. Patients with chronic diseases are frequent users of medical care, accounting for 81 percent of hospital admissions and 76 percent of physician visits. Treating these diseases is hugely expensive with 86 cents of every health care dollar spent in the United States going toward treating chronic illness, and the scope and severity of the problem is o...
Source: The Catalyst - February 25, 2016 Category: Pharmaceuticals Tags: Medicines in Development Innovation new medicines diabetes chronic disease HIV/AIDS Multiple Sclerosis Rheumatoid Arthritis Hepatitis C high cholesterol Source Type: news

FDA Clears Extended-Release Tofacitinib (Xeljanz XR) for RAFDA Clears Extended-Release Tofacitinib (Xeljanz XR) for RA
Xeljanz XR provides a once-daily oral option for patients with moderate to severe rheumatoid arthritis. FDA Approvals (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 25, 2016 Category: Allergy & Immunology Tags: Rheumatology News Alert Source Type: news

Pfizer receives FDA approval for Xeljanz XR to treat rheumatoid arthritis
Pfizer has received the US Food and Drug Administration (FDA) approval for its Xeljanz XR (tofacitinib citrate) extended-release tablets for the treatment of rheumatoid arthritis (RA). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 25, 2016 Category: Pharmaceuticals Source Type: news

Pfizer Announces FDA Approval of Xeljanz XR (tofacitinib citrate), the First and Only Once-Daily Oral JAK Inhibitor Treatment for Rheumatoid Arthritis
February 24, 2016 -- Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Xeljanz XR (tofacitinib citrate) extended-release 11 mg tablets for the once-daily treatment of moderate to severe rheumatoid... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 24, 2016 Category: Drugs & Pharmacology Source Type: news

Influenza viruses can hide from the immune system
Influenza is able to mask itself, so that the virus is not initially detected by our immune system, a new study shows. The researchers behind the study hope that the discovery can be used to develop better treatment against influenza and chronic inflammation conditions such as rheumatoid arthritis. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 23, 2016 Category: Science Source Type: news

Lyme: The Infectious Disease Equivalent of Cancer, Says Top Duke Oncologist
Last week, I mentioned the case of Dr. Neil Spector, whose long-undiagnosed Lyme Disease resulted in irreversible heart failure and ultimately, a heart transplant. Dr. Spector, author of Gone in a Heartbeat: A Physician's Search for True Healing, is the Sandra Coates Associate Professor of Medicine and Associate Professor of Pharmacology and Cancer Biology at Duke University School of Medicine. As the Director of Developmental Therapeutics at the Duke Cancer Institute, he's a leader in applying translational research to the clinical development of molecularly targeted personalized cancer therapies. Here, Dr. Spector share...
Source: Science - The Huffington Post - February 19, 2016 Category: Science Source Type: news

Key mechanism explored to treat autoimmune diseases
A new study could change the way researchers understand and treat autoimmune diseases such as type 1 diabetes, multiple sclerosis and rheumatoid arthritis. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 19, 2016 Category: Science Source Type: news

Periodontitis Linked With Childhood Arthritis (CME/CE)
(MedPage Today) -- Similar to the association in seropositive adult-onset rheumatoid arthritis (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 19, 2016 Category: Primary Care Source Type: news